AstraZeneca bets up to $443M on Omthera lipid drug

Pipeline-starved AstraZeneca ($AZN) snapped up Omthera ($OMTH) in a deal worth up to $443 million, on hopes for the company's omega-3 cardio drug Epanova. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.